GPT and liver disorder: Patient 1 experienced a mild liver disorder on day 337 (alanine aminotransferase [ALT] and aspartate aminotransferase [AST] levels were 113 U/L and 86 U/L, respectively, at baseline and 44 U/L and 47 U/L, respectively, at week 24 of cycle 1, which increased to 391 U/L and 236 U/L, respectively, at week 24 of cycle 2), which was not considered related to the study drug.